CLIFTON, NJ / ACCESSWIRE / January 26, 2016 / mPhase Technologies, Inc. (OTC: XDSL) (http://www.mPhaseTech.com) said today that its new, patented Drug Delivery System could prove especially useful and efficacious for patients taking insulin for diabetes, according to Company research.
Ronald A. Durando, the Company's Chairman, President and CEO, said mPhase Technologies' new invention automatically dispenses a pre-set dosage of a drug such as insulin, which is vital in maintaining proper blood sugar levels in individuals with diabetes. "Every method to deliver insulin currently used has proven to have some problems," Mr. Durando explains.
"Some patients use insulin pens which are pre-filled with insulin." Mr. Durando said. "Syringes may still be the most common way to deliver insulin. Problems include the number of steps needed to be taken before the injection: and drawing the correct dose of insulin into the syringe. Because both of these methods are done manually, human errors occur and sometimes the correct dosage is not administered."
"The insulin pump, delivers a steady stream of insulin 24 hours a day along with the user calculating meal bolus amounts. Disadvantages of the pump can be that one must frequently change the needle to avoid infection, dosing errors, and some people are not comfortable having the unit attached to them 24 hours a day," the mPhase Technologies CEO said. Additionally, blood sugar levels need to be tracked frequently for drops in blood sugar.
"A jet injector is used by people who hate needles, but it can be painful and does not always deliver an accurate dose. Inhaled insulin can prove risky for those who smoke or have any lung problems," Mr. Durando said.
In addition, new methods of delivering insulin have been introduced that deliver dosing through the skin, with very fine needles that penetrate the skin. In addition, new Insulin Patches are also being explored that use various methods to drive insulin through the skin. They work in a similar way to nicotine patches used by smokers to help them quit.
"Now that we have received a Notice of Allowance of a Patent for our new Drug Delivery System, we look forward to discussing our product with major drug companies," Mr. Durando concluded.
About mPhase Technologies, Inc.: mPhase Technologies Inc. is a publicly traded company pioneering a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications in drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems and filtration systems.
Forward-Looking Statements: Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase Technologies assumes no obligation to update the information in this release.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
SOURCE: mPhase Technologies, Inc.